Group 1 - The core point of the article is that Boya Bio (SZ 300294) held its 16th meeting of the 8th Board of Directors on October 27, 2025, to review the performance contracts for the management team for the year 2025 [1] - For the first half of 2025, Boya Bio's revenue composition is as follows: blood products account for 84.58%, biochemical drugs for 8.63%, pharmaceutical distribution for 6.12%, other industries for 0.65%, and other businesses for 0.02% [1] - As of the report date, Boya Bio has a market capitalization of 12.4 billion yuan [1]